Ensuring the Viability of AI in Real-World Applications Falls on the Shoulders of AI Accelerators

Hedera

 

The AI industry is at a pivotal moment where the successful deployment of AI in real-world applications hinges on a delicate balance of software, hardware, intelligence, and applications. The race to harness AI’s full potential intensifies, with AI accelerators playing a crucial role in supporting heavy-compute applications or facilitating intense AI learning and training. The stakes are high as businesses navigate the complexities of AI infrastructure to gain a competitive edge.

How crucial are AI accelerators in the viability of AI in real-world applications, and what are the economic implications of their implementation?

In a recent Expert Talks roundtable, Grant Powell, the Founder at Curios, and David Fellows, the Chief Digital Officer at Acuity Knowledge Partners, provided valuable insights into this topic. Their analysis sheds light on the multifaceted role of AI accelerators and the economic considerations involved.

Key Takeaways from the Experts:

  • Components of the Viability of AI in Real-World Applications depend on a synergy of hardware, software (intelligence), and the data fed into this intelligence, along with the applications of AI. This holistic view underscores the interdependence of various components in creating effective AI solutions.
  • Fundamental Importance of AI Accelerators: AI accelerators are fundamental because all AI infrastructure will either support or incorporate AI to transform industries.
  • Economic Considerations: The cost of computing and the commercial models available are key factors influencing the adoption and implementation of AI technologies. Open-source models present an alternative with varying cost implications.
  • Quality vs. Cost: Balance the quality and output of AI models with their associated costs. This involves assessing both the performance of the models and the financial investment required to achieve desired outcomes.
  • Analogy to the Space Race: Like the space race, the rapid evolution of AI technology is a relentless pace of change and innovation.

For a comprehensive analysis of this topic and more insights from industry experts, refer to the complete expert roundtable discussion here.

Article by MarketScale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More